{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T21:40:52Z","timestamp":1790977252741,"version":"4.1.0"},"reference-count":105,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T00:00:00Z","timestamp":1664150400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T00:00:00Z","timestamp":1664150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100000156","name":"Fonds de Recherche du Qu\u00e9bec - Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["#PJ8-169696"],"award-info":[{"award-number":["#PJ8-169696"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PJT-175191"],"award-info":[{"award-number":["PJT-175191"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s40263-022-00952-y","type":"journal-article","created":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T07:03:35Z","timestamp":1664175815000},"page":"1049-1077","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Psychotropic Drugs and Adverse Kidney Effects: A Systematic Review of the Past Decade of Research"],"prefix":"10.1007","volume":"36","author":[{"given":"Joseph Junior","family":"Damba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Bodenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Lavin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Drury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harmehr","family":"Sekhon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christel","family":"Renoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Trinh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soham","family":"Rej","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7829-493X","authenticated-orcid":false,"given":"Kyle T.","family":"Greenway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,26]]},"reference":[{"issue":"4","key":"952_CR1","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1007\/s12325-009-0021-x","volume":"26","author":"NT Baghdady","year":"2009","unstructured":"Baghdady NT, Banik S, Swartz SA, McIntyre RS. Psychotropic drugs and renal failure: translating the evidence for clinical practice. Adv Ther. 2009;26(4):404\u201324. https:\/\/doi.org\/10.1007\/s12325-009-0021-x.","journal-title":"Adv Ther"},{"issue":"1","key":"952_CR2","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s12877-019-1126-y","volume":"19","author":"MT Lornstad","year":"2019","unstructured":"Lornstad MT, Aaroen M, Bergh S, Benth JS, Helvik AS. Prevalence and persistent use of psychotropic drugs in older adults receiving domiciliary care at baseline. BMC Geriatr. 2019;19(1):119. https:\/\/doi.org\/10.1186\/s12877-019-1126-y.","journal-title":"BMC Geriatr"},{"issue":"4","key":"952_CR3","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1002\/phar.2513","volume":"41","author":"MR Morris","year":"2021","unstructured":"Morris MR, Hoeflich CC, Nutley S, Ellingrod VL, Riba MB, Striley CW. Use of psychiatric medication by college students: a decade of data. Pharmacotherapy. 2021;41(4):350\u20138. https:\/\/doi.org\/10.1002\/phar.2513.","journal-title":"Pharmacotherapy"},{"key":"952_CR4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jad.2021.03.022","volume":"287","author":"TXD Cao","year":"2021","unstructured":"Cao TXD, Fraga LFC, Fergusson E, Michaud J, Dell\u2019Aniello S, Yin H, et al. Prescribing trends of antidepressants and psychotropic coprescription for youths in UK primary care, 2000\u20132018. J Affect Disord. 2021;287:19\u201325. https:\/\/doi.org\/10.1016\/j.jad.2021.03.022.","journal-title":"J Affect Disord"},{"key":"952_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.727453","volume":"12","author":"L Xu","year":"2021","unstructured":"Xu L, Lv X, Wang H, Liu Q, Zhou S, Gao S, et al. Trends in psychotropic medication prescriptions in urban China from 2013 to 2017: national population-based study. Front Psychiatry. 2021;12: 727453. https:\/\/doi.org\/10.3389\/fpsyt.2021.727453.","journal-title":"Front Psychiatry."},{"issue":"2","key":"952_CR6","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1001\/jamainternmed.2016.7507","volume":"177","author":"TJ Moore","year":"2017","unstructured":"Moore TJ, Mattison DR. Adult utilization of psychiatric drugs and differences by sex, age, and race. JAMA Intern Med. 2017;177(2):274\u20135. https:\/\/doi.org\/10.1001\/jamainternmed.2016.7507.","journal-title":"JAMA Intern Med"},{"issue":"12","key":"952_CR7","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.2165\/11530020-000000000-00000","volume":"23","author":"CG Bhuvaneswar","year":"2009","unstructured":"Bhuvaneswar CG, Baldessarini RJ, Harsh VL, Alpert JE. Adverse endocrine and metabolic effects of psychotropic drugs: selective clinical review. CNS Drugs. 2009;23(12):1003\u201321. https:\/\/doi.org\/10.2165\/11530020-000000000-00000.","journal-title":"CNS Drugs"},{"issue":"7","key":"952_CR8","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1097\/01.chi.0000220851.94392.30","volume":"45","author":"CU Correll","year":"2006","unstructured":"Correll CU, Carlson HE. Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry. 2006;45(7):771\u201391. https:\/\/doi.org\/10.1097\/01.chi.0000220851.94392.30.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"5","key":"952_CR9","first-page":"617","volume":"81","author":"J Muench","year":"2010","unstructured":"Muench J, Hamer AM. Adverse effects of antipsychotic medications. Am Fam Physician. 2010;81(5):617\u201322.","journal-title":"Am Fam Physician"},{"issue":"12","key":"952_CR10","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1001\/archpsyc.1991.01810360046007","volume":"48","author":"T Suppes","year":"1991","unstructured":"Suppes T, Baldessarini RJ, Faedda GL, Tohen M. Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. Arch Gen Psychiatry. 1991;48(12):1082\u20138. https:\/\/doi.org\/10.1001\/archpsyc.1991.01810360046007.","journal-title":"Arch Gen Psychiatry"},{"issue":"8","key":"952_CR11","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1176\/appi.ajp.2018.17091001","volume":"175","author":"J Tiihonen","year":"2018","unstructured":"Tiihonen J, Tanskanen A, Taipale H. 20-Year nationwide follow-up study on discontinuation of antipsychotic treatment in first-episode schizophrenia. Am J Psychiatry. 2018;175(8):765\u201373. https:\/\/doi.org\/10.1176\/appi.ajp.2018.17091001.","journal-title":"Am J Psychiatry"},{"issue":"1","key":"952_CR12","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12888-018-1622-1","volume":"18","author":"L Ohlund","year":"2018","unstructured":"Ohlund L, Ott M, Oja S, Bergqvist M, Lundqvist R, Sandlund M, et al. Reasons for lithium discontinuation in men and women with bipolar disorder: a retrospective cohort study. BMC Psychiatry. 2018;18(1):37. https:\/\/doi.org\/10.1186\/s12888-018-1622-1.","journal-title":"BMC Psychiatry"},{"key":"952_CR13","doi-asserted-by":"publisher","first-page":"377","DOI":"10.3389\/fpsyt.2020.00377","volume":"11","author":"C Volkmann","year":"2020","unstructured":"Volkmann C, Bschor T, Kohler S. Lithium treatment over the lifespan in bipolar disorders. Front Psychiatry. 2020;11:377. https:\/\/doi.org\/10.3389\/fpsyt.2020.00377.","journal-title":"Front Psychiatry."},{"issue":"7","key":"952_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0158765","volume":"11","author":"NR Hill","year":"2016","unstructured":"Hill NR, Fatoba ST, Oke JL, Hirst JA, O\u2019Callaghan CA, Lasserson DS, et al. Global prevalence of chronic kidney disease: a systematic review and meta-analysis. PLoS ONE. 2016;11(7): e0158765. https:\/\/doi.org\/10.1371\/journal.pone.0158765.","journal-title":"PLoS ONE"},{"key":"952_CR15","unstructured":"Centers for Disease Control and Prevention. Chronic kidney disease in the United States, 2021. https:\/\/www.cdc.gov\/kidneydisease\/publications-resources\/ckd-national-facts.html. Accessed 26 Mar 2022."},{"issue":"10225","key":"952_CR16","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","volume":"395","author":"GBD Chronic Kidney Disease Collaboration","year":"2020","unstructured":"GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020;395(10225):709\u201333. https:\/\/doi.org\/10.1016\/S0140-6736(20)30045-3.","journal-title":"Lancet"},{"issue":"1","key":"952_CR17","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ekir.2016.09.005","volume":"2","author":"S Shirazian","year":"2017","unstructured":"Shirazian S, Grant CD, Aina O, Mattana J, Khorassani F, Ricardo AC. Depression in chronic kidney disease and end-stage renal disease: similarities and differences in diagnosis, epidemiology, and management. Kidney Int Rep. 2017;2(1):94\u2013107. https:\/\/doi.org\/10.1016\/j.ekir.2016.09.005.","journal-title":"Kidney Int Rep."},{"issue":"1","key":"952_CR18","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1177\/0891988712436690","volume":"25","author":"S Rej","year":"2012","unstructured":"Rej S, Herrmann N, Shulman K. The effects of lithium on renal function in older adults: a systematic review. J Geriatr Psychiatry Neurol. 2012;25(1):51\u201361. https:\/\/doi.org\/10.1177\/0891988712436690.","journal-title":"J Geriatr Psychiatry Neurol"},{"issue":"9817","key":"952_CR19","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/S0140-6736(11)61516-X","volume":"379","author":"RF McKnight","year":"2012","unstructured":"McKnight RF, Adida M, Budge K, Stockton S, Goodwin GM, Geddes JR. Lithium toxicity profile: a systematic review and meta-analysis. Lancet. 2012;379(9817):721\u20138. https:\/\/doi.org\/10.1016\/S0140-6736(11)61516-X.","journal-title":"Lancet"},{"issue":"1","key":"952_CR20","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1186\/s12882-018-1101-4","volume":"19","author":"J Davis","year":"2018","unstructured":"Davis J, Desmond M, Berk M. Lithium and nephrotoxicity: a literature review of approaches to clinical management and risk stratification. BMC Nephrol. 2018;19(1):305. https:\/\/doi.org\/10.1186\/s12882-018-1101-4.","journal-title":"BMC Nephrol"},{"issue":"1","key":"952_CR21","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1471-244X-14-4","volume":"14","author":"C Rodrigo","year":"2014","unstructured":"Rodrigo C, de Silva NL, Gunaratne R, Rajapakse S, De Silva VA, Hanwella R. Lower estimated glomerular filtration rates in patients on long term lithium: a comparative study and a meta-analysis of literature. BMC Psychiatry. 2014;14(1):4. https:\/\/doi.org\/10.1186\/1471-244X-14-4.","journal-title":"BMC Psychiatry"},{"issue":"10","key":"952_CR22","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1177\/0269881109104930","volume":"24","author":"R Paul","year":"2010","unstructured":"Paul R, Minay J, Cardwell C, Fogarty D, Kelly C. Meta-analysis of the effects of lithium usage on serum creatinine levels. J Psychopharmacol. 2010;24(10):1425\u201331. https:\/\/doi.org\/10.1177\/0269881109104930.","journal-title":"J Psychopharmacol"},{"issue":"1","key":"952_CR23","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s40345-015-0028-y","volume":"3","author":"AN Azab","year":"2015","unstructured":"Azab AN, Shnaider A, Osher Y, Wang D, Bersudsky Y, Belmaker RH. Lithium nephrotoxicity. Int J Bipolar Disord. 2015;3(1):28. https:\/\/doi.org\/10.1186\/s40345-015-0028-y.","journal-title":"Int J Bipolar Disord"},{"issue":"4","key":"952_CR24","doi-asserted-by":"publisher","first-page":"242","DOI":"10.7326\/M13-2796","volume":"161","author":"YJ Hwang","year":"2014","unstructured":"Hwang YJ, Dixon SN, Reiss JP, Wald R, Parikh CR, Gandhi S, et al. Atypical antipsychotic drugs and the risk for acute kidney injury and other adverse outcomes in older adults: a population-based cohort study. Ann Intern Med. 2014;161(4):242\u20138. https:\/\/doi.org\/10.7326\/M13-2796.","journal-title":"Ann Intern Med"},{"issue":"3","key":"952_CR25","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s40266-016-0430-x","volume":"34","author":"PB Ryan","year":"2017","unstructured":"Ryan PB, Schuemie MJ, Ramcharran D, Stang PE. Atypical antipsychotics and the risks of acute kidney injury and related outcomes among older adults: a replication analysis and an evaluation of adapted confounding control strategies. Drugs Aging. 2017;34(3):211\u20139. https:\/\/doi.org\/10.1007\/s40266-016-0430-x.","journal-title":"Drugs Aging"},{"issue":"1","key":"952_CR26","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/jcpt.12357","volume":"41","author":"N El-Saifi","year":"2016","unstructured":"El-Saifi N, Moyle W, Jones C, Tuffaha H. Quetiapine safety in older adults: a systematic literature review. J Clin Pharm Ther. 2016;41(1):7\u201318. https:\/\/doi.org\/10.1111\/jcpt.12357.","journal-title":"J Clin Pharm Ther"},{"issue":"2","key":"952_CR27","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1177\/0269881113516202","volume":"28","author":"H Aiff","year":"2014","unstructured":"Aiff H, Attman PO, Aurell M, Bendz H, Schon S, Svedlund J. The impact of modern treatment principles may have eliminated lithium-induced renal failure. J Psychopharmacol. 2014;28(2):151\u20134. https:\/\/doi.org\/10.1177\/0269881113516202.","journal-title":"J Psychopharmacol"},{"issue":"3","key":"952_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0090169","volume":"9","author":"H Close","year":"2014","unstructured":"Close H, Reilly J, Mason JM, Kripalani M, Wilson D, Main J, et al. Renal failure in lithium-treated bipolar disorder: a retrospective cohort study. PLoS ONE. 2014;9(3): e90169. https:\/\/doi.org\/10.1371\/journal.pone.0090169.","journal-title":"PLoS ONE"},{"issue":"1","key":"952_CR29","doi-asserted-by":"publisher","first-page":"30","DOI":"10.5694\/mja13.10435","volume":"201","author":"M Roxanas","year":"2014","unstructured":"Roxanas M, Grace BS, George CR. Renal replacement therapy associated with lithium nephrotoxicity in Australia. Med J Aust. 2014;201(1):30\u20131. https:\/\/doi.org\/10.5694\/mja13.10435.","journal-title":"Med J Aust"},{"issue":"6","key":"952_CR30","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1111\/acps.12820","volume":"136","author":"LV Kessing","year":"2017","unstructured":"Kessing LV, Feldt-Rasmussen B, Andersen PK, Gerds TA, Licht RW. Continuation of lithium after a diagnosis of chronic kidney disease. Acta Psychiatr Scand. 2017;136(6):615\u201322. https:\/\/doi.org\/10.1111\/acps.12820.","journal-title":"Acta Psychiatr Scand"},{"issue":"12","key":"952_CR31","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1001\/jamapsychiatry.2015.1834","volume":"72","author":"LV Kessing","year":"2015","unstructured":"Kessing LV, Gerds TA, Feldt-Rasmussen B, Andersen PK, Licht RW. Use of lithium and anticonvulsants and the rate of chronic kidney disease: a nationwide population-based study. JAMA Psychiat. 2015;72(12):182\u201391. https:\/\/doi.org\/10.1001\/jamapsychiatry.2015.1834.","journal-title":"JAMA Psychiat"},{"issue":"2","key":"952_CR32","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1159\/000514550","volume":"52","author":"JS Thurlow","year":"2021","unstructured":"Thurlow JS, Joshi M, Yan G, Norris KC, Agodoa LY, Yuan CM, et al. Global epidemiology of end-stage kidney disease and disparities in kidney replacement therapy. Am J Nephrol. 2021;52(2):98\u2013107. https:\/\/doi.org\/10.1159\/000514550.","journal-title":"Am J Nephrol"},{"issue":"1","key":"952_CR33","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1186\/s12882-017-0794-0","volume":"18","author":"K Mansoor","year":"2017","unstructured":"Mansoor K, Kheetan M, Shahnawaz S, Shapiro AP, Patton-Tackett E, Dial L, et al. Systematic review of nephrotoxicity of drugs of abuse, 2005\u20132016. BMC Nephrol. 2017;18(1):379. https:\/\/doi.org\/10.1186\/s12882-017-0794-0.","journal-title":"BMC Nephrol"},{"key":"952_CR34","unstructured":"Centre for Evidence-Based Medicine. Oxford Centre for Evidence-Based Medicine: levels of evidence. 2009. https:\/\/www.cebm.ox.ac.uk\/resources\/levels-of-evidence\/oxford-centre-for-evidence-based-medicine-levels-of-evidence-march-2009. Accessed 27 Feb 2022."},{"issue":"1","key":"952_CR35","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40779-020-00238-8","volume":"7","author":"LL Ma","year":"2020","unstructured":"Ma LL, Wang YY, Yang ZH, Huang D, Weng H, Zeng XT. Methodological quality (risk of bias) assessment tools for primary and secondary medical studies: what are they and which is better? Mil Med Res. 2020;7(1):7. https:\/\/doi.org\/10.1186\/s40779-020-00238-8.","journal-title":"Mil Med Res"},{"key":"952_CR36","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovic J, Page KJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366: l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"issue":"7","key":"952_CR37","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1111\/bdi.13052","volume":"23","author":"M Pahwa","year":"2021","unstructured":"Pahwa M, Joseph B, Nunez NA, Jenkins GD, Colby CL, Kashani KB, et al. Long-term lithium therapy and risk of chronic kidney disease in bipolar disorder: a historical cohort study. Bipolar Disord. 2021;23(7):715\u201323. https:\/\/doi.org\/10.1111\/bdi.13052.","journal-title":"Bipolar Disord"},{"issue":"3","key":"952_CR38","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1111\/jgs.15740","volume":"67","author":"JH Ishida","year":"2019","unstructured":"Ishida JH, McCulloch CE, Steinman MA, Grimes BA, Johansen KL. Psychoactive medications and adverse outcomes among older adults receiving hemodialysis. J Am Geriatr Soc. 2019;67(3):449\u201354. https:\/\/doi.org\/10.1111\/jgs.15740.","journal-title":"J Am Geriatr Soc"},{"issue":"11","key":"952_CR39","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-006020","volume":"4","author":"E Kirkham","year":"2014","unstructured":"Kirkham E, Skinner J, Anderson T, Bazire S, Twigg MJ, Desborough JA. One lithium level >1.0 mmol\/L causes an acute decline in eGFR: findings from a retrospective analysis of a monitoring database. BMJ Open. 2014;4(11): e006020. https:\/\/doi.org\/10.1136\/bmjopen-2014-006020.","journal-title":"BMJ Open"},{"issue":"10","key":"952_CR40","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1177\/0269881116652577","volume":"30","author":"M Ott","year":"2016","unstructured":"Ott M, Stegmayr B, Salander Renberg E, Werneke U. Lithium intoxication: incidence, clinical course and renal function: a population-based retrospective cohort study. J Psychopharmacol. 2016;30(10):1008\u201319. https:\/\/doi.org\/10.1177\/0269881116652577.","journal-title":"J Psychopharmacol"},{"issue":"12","key":"952_CR41","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1093\/qjmed\/hcx171","volume":"110","author":"R Dineen","year":"2017","unstructured":"Dineen R, Bogdanet D, Thompson D, Thompson CJ, Behan LA, McKay AP, et al. Endocrinopathies and renal outcomes in lithium therapy: impact of lithium toxicity. QJM. 2017;110(12):821\u20137. https:\/\/doi.org\/10.1093\/qjmed\/hcx171.","journal-title":"QJM"},{"issue":"2","key":"952_CR42","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1093\/ckj\/sfv132","volume":"9","author":"S Sajadi","year":"2016","unstructured":"Sajadi S, Yu C, Sylvestre JD, Looper KJ, Segal M, Rej S. Does lower urine-specific gravity predict decline in renal function and hypernatremia in older adults exposed to psychotropic medications? An exploratory analysis. Clin Kidney J. 2016;9(2):268\u201372. https:\/\/doi.org\/10.1093\/ckj\/sfv132.","journal-title":"Clin Kidney J"},{"issue":"11","key":"952_CR43","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/j.jagp.2014.01.015","volume":"22","author":"S Rej","year":"2014","unstructured":"Rej S, Shulman K, Herrmann N, Harel Z, Fischer HD, Fung K, et al. Prevalence and correlates of renal disease in older lithium users: a population-based study. Am J Geriatr Psychiatry. 2014;22(11):1075\u201382. https:\/\/doi.org\/10.1016\/j.jagp.2014.01.015.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"1","key":"952_CR44","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1741-7015-11-33","volume":"11","author":"A Bocchetta","year":"2013","unstructured":"Bocchetta A, Ardau R, Carta P, Ligas F, Sardu C, Pani A, et al. Duration of lithium treatment is a risk factor for reduced glomerular function: a cross-sectional study. BMC Med. 2013;11(1):33. https:\/\/doi.org\/10.1186\/1741-7015-11-33.","journal-title":"BMC Med"},{"issue":"6","key":"952_CR45","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.genhosppsych.2012.10.016","volume":"35","author":"J Minay","year":"2013","unstructured":"Minay J, Paul R, McGarvey D, Savage G, Stevenson M, Fogarty D, et al. Lithium usage and renal function testing in a large UK community population; a case-control study. Gen Hosp Psychiatry. 2013;35(6):631\u20135. https:\/\/doi.org\/10.1016\/j.genhosppsych.2012.10.016.","journal-title":"Gen Hosp Psychiatry"},{"issue":"7","key":"952_CR46","doi-asserted-by":"publisher","first-page":"e672","DOI":"10.4088\/JCP.13m08741","volume":"75","author":"I Aprahamian","year":"2014","unstructured":"Aprahamian I, Santos FS, dos Santos B, Talib L, Diniz BS, Radanovic M, et al. Long-term, low-dose lithium treatment does not impair renal function in the elderly: a 2-year randomized, placebo-controlled trial followed by single-blind extension. J Clin Psychiatry. 2014;75(7):e672\u20138. https:\/\/doi.org\/10.4088\/JCP.13m08741.","journal-title":"J Clin Psychiatry"},{"issue":"12","key":"952_CR47","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/S2215-0366(15)00316-8","volume":"2","author":"S Clos","year":"2015","unstructured":"Clos S, Rauchhaus P, Severn A, Cochrane L, Donnan PT. Long-term effect of lithium maintenance therapy on estimated glomerular filtration rate in patients with affective disorders: a population-based cohort study. Lancet Psychiatry. 2015;2(12):1075\u201383. https:\/\/doi.org\/10.1016\/S2215-0366(15)00316-8.","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"952_CR48","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s40345-017-0096-2","volume":"5","author":"L Tondo","year":"2017","unstructured":"Tondo L, Abramowicz M, Alda M, Bauer M, Bocchetta A, Bolzani L, et al. Long-term lithium treatment in bipolar disorder: effects on glomerular filtration rate and other metabolic parameters. Int J Bipolar Disord. 2017;5(1):27. https:\/\/doi.org\/10.1186\/s40345-017-0096-2.","journal-title":"Int J Bipolar Disord."},{"issue":"1","key":"952_CR49","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40345-017-0114-4","volume":"6","author":"A Bocchetta","year":"2018","unstructured":"Bocchetta A, Ambrosiani L, Baggiani G, Pisanu C, Chillotti C, Ardau R, et al. Circulating antithyroid antibodies contribute to the decrease of glomerular filtration rate in lithium-treated patients: a longitudinal study. Int J Bipolar Disord. 2018;6(1):3. https:\/\/doi.org\/10.1186\/s40345-017-0114-4.","journal-title":"Int J Bipolar Disord."},{"issue":"4","key":"952_CR50","first-page":"139","volume":"77","author":"J Doornebal","year":"2019","unstructured":"Doornebal J, Diepenbroek A, van de Luijtgaarden MWM, Hartong E, Grootens KP, Kupka RW, et al. Renal concentrating ability and glomerular filtration rate in lithium-treated patients. Neth J Med. 2019;77(4):139\u201349.","journal-title":"Neth J Med"},{"issue":"5","key":"952_CR51","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/s0272-6386(87)80098-7","volume":"10","author":"R Boton","year":"1987","unstructured":"Boton R, Gaviria M, Batlle DC. Prevalence, pathogenesis, and treatment of renal dysfunction associated with chronic lithium therapy. Am J Kidney Dis. 1987;10(5):329\u201345. https:\/\/doi.org\/10.1016\/s0272-6386(87)80098-7.","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"952_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40345-020-00204-2","volume":"9","author":"AM Van Alphen","year":"2021","unstructured":"Van Alphen AM, Bosch TM, Kupka RW, Hoekstra R. Chronic kidney disease in lithium-treated patients, incidence and rate of decline. Int J Bipolar Disord. 2021;9(1):1. https:\/\/doi.org\/10.1186\/s40345-020-00204-2.","journal-title":"Int J Bipolar Disord."},{"issue":"1","key":"952_CR53","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s12916-021-01964-z","volume":"19","author":"JF Hayes","year":"2021","unstructured":"Hayes JF, Osborn DPJ, Francis E, Ambler G, Tomlinson LA, Boman M, et al. Prediction of individuals at high risk of chronic kidney disease during treatment with lithium for bipolar disorder. BMC Med. 2021;19(1):99. https:\/\/doi.org\/10.1186\/s12916-021-01964-z.","journal-title":"BMC Med"},{"issue":"5","key":"952_CR54","doi-asserted-by":"publisher","first-page":"18","DOI":"10.4088\/JCP.19m13045","volume":"81","author":"S Rej","year":"2020","unstructured":"Rej S, Herrmann N, Gruneir A, McArthur E, Jeyakumar N, Muanda FT, et al. Association of lithium use and a higher serum concentration of lithium with the risk of declining renal function in older adults: a population-based cohort study. J Clin Psychiatry. 2020;81(5):18. https:\/\/doi.org\/10.4088\/JCP.19m13045.","journal-title":"J Clin Psychiatry"},{"issue":"8","key":"952_CR55","doi-asserted-by":"publisher","first-page":"e980","DOI":"10.4088\/JCP.16m11125","volume":"78","author":"S Rej","year":"2017","unstructured":"Rej S, Herrmann N, Shulman K, Fischer HD, Fung K, Harel Z, et al. Lithium use, but not valproate use, is associated with a higher risk of chronic kidney disease in older adults with mental illness. J Clin Psychiatry. 2017;78(8):e980\u20135. https:\/\/doi.org\/10.4088\/JCP.16m11125.","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"952_CR56","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40345-017-0089-1","volume":"5","author":"A Bocchetta","year":"2017","unstructured":"Bocchetta A, Cabras F, Pinna M, Poddighe A, Sardu C, Ardau R, et al. An observational study of 110 elderly lithium-treated patients followed up for 6 years with particular reference to renal function. Int J Bipolar Disord. 2017;5(1):19. https:\/\/doi.org\/10.1186\/s40345-017-0089-1.","journal-title":"Int J Bipolar Disord."},{"issue":"8","key":"952_CR57","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002058","volume":"13","author":"JF Hayes","year":"2016","unstructured":"Hayes JF, Marston L, Walters K, Geddes JR, King M, Osborn DP. Adverse renal, endocrine, hepatic, and metabolic events during maintenance mood stabilizer treatment for bipolar disorder: a population-based cohort study. PLoS Med. 2016;13(8): e1002058. https:\/\/doi.org\/10.1371\/journal.pmed.1002058.","journal-title":"PLoS Med"},{"issue":"5","key":"952_CR58","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1177\/0269881115573808","volume":"29","author":"H Aiff","year":"2015","unstructured":"Aiff H, Attman PO, Aurell M, Bendz H, Ramsauer B, Schon S, et al. Effects of 10 to 30 years of lithium treatment on kidney function. J Psychopharmacol. 2015;29(5):608\u201314. https:\/\/doi.org\/10.1177\/0269881115573808.","journal-title":"J Psychopharmacol"},{"issue":"9992","key":"952_CR59","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S0140-6736(14)61842-0","volume":"386","author":"B Shine","year":"2015","unstructured":"Shine B, McKnight RF, Leaver L, Geddes JR. Long-term effects of lithium on renal, thyroid, and parathyroid function: a retrospective analysis of laboratory data. Lancet. 2015;386(9992):461\u20138. https:\/\/doi.org\/10.1016\/S0140-6736(14)61842-0.","journal-title":"Lancet"},{"issue":"1","key":"952_CR60","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12916-014-0249-4","volume":"13","author":"A Bocchetta","year":"2015","unstructured":"Bocchetta A, Ardau R, Fanni T, Sardu C, Piras D, Pani A, et al. Renal function during long-term lithium treatment: a cross-sectional and longitudinal study. BMC Med. 2015;13(1):12. https:\/\/doi.org\/10.1186\/s12916-014-0249-4.","journal-title":"BMC Med"},{"issue":"4","key":"952_CR61","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1038\/npp.2015.254","volume":"41","author":"VM Castro","year":"2016","unstructured":"Castro VM, Roberson AM, McCoy TH, Wiste A, Cagan A, Smoller JW, et al. Stratifying risk for renal insufficiency among lithium-treated patients: an electronic health record study. Neuropsychopharmacology. 2016;41(4):1138\u201343. https:\/\/doi.org\/10.1038\/npp.2015.254.","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"952_CR62","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/bdi.12235","volume":"17","author":"JC Kinahan","year":"2015","unstructured":"Kinahan JC, NiChorcorain A, Cunningham S, Freyne A, Cooney C, Barry S, et al. Risk factors for polyuria in a cross-section of community psychiatric lithium-treated patients. Bipolar Disord. 2015;17(1):50\u201362. https:\/\/doi.org\/10.1111\/bdi.12235.","journal-title":"Bipolar Disord"},{"issue":"6","key":"952_CR63","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1177\/070674371405900606","volume":"59","author":"S Rej","year":"2014","unstructured":"Rej S, Segal M, Low NC, Mucsi I, Holcroft C, Shulman K, et al. The McGill Geriatric Lithium-Induced Diabetes Insipidus Clinical Study (McGLIDICS). Can J Psychiatry. 2014;59(6):327\u201334. https:\/\/doi.org\/10.1177\/070674371405900606.","journal-title":"Can J Psychiatry"},{"issue":"no pagination","key":"952_CR64","doi-asserted-by":"publisher","DOI":"10.1177\/2045125319836563","volume":"9","author":"M Ott","year":"2019","unstructured":"Ott M, Forssen B, Werneke U. Lithium treatment, nephrogenic diabetes insipidus and the risk of hypernatraemia: a retrospective cohort study. Ther Adv Psychopharmacol. 2019;9(no pagination): 2045125319836563. https:\/\/doi.org\/10.1177\/2045125319836563.","journal-title":"Ther Adv Psychopharmacol."},{"issue":"4","key":"952_CR65","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.euroneuro.2014.01.002","volume":"24","author":"H Aiff","year":"2014","unstructured":"Aiff H, Attman PO, Aurell M, Bendz H, Schon S, Svedlund J. End-stage renal disease associated with prophylactic lithium treatment. Eur Neuropsychopharmacol. 2014;24(4):540\u20134. https:\/\/doi.org\/10.1016\/j.euroneuro.2014.01.002.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"10007","key":"952_CR66","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1016\/S0140-6736(15)00835-1","volume":"386","author":"B Shine","year":"2015","unstructured":"Shine B, McKnight R, Leaver L, Geddes J. Long-term effects of lithium on renal function: authors\u2019 reply. Lancet. 2015;386(10007):1944. https:\/\/doi.org\/10.1016\/S0140-6736(15)00835-1.","journal-title":"Lancet"},{"issue":"1","key":"952_CR67","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2215\/CJN.07490618","volume":"14","author":"K Yau","year":"2019","unstructured":"Yau K, Burneo JG, Jandoc R, McArthur E, Muanda FT, Parikh CR, et al. Population-based study of risk of AKI with levetiracetam. Clin J Am Soc Nephrol. 2019;14(1):17\u201326. https:\/\/doi.org\/10.2215\/CJN.07490618.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"952_CR68","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-006777","volume":"5","author":"NS Tzeng","year":"2015","unstructured":"Tzeng NS, Hsu YH, Ho SY, Kuo YC, Lee HC, Yin YJ, et al. Is schizophrenia associated with an increased risk of chronic kidney disease? A nationwide matched-cohort study. BMJ Open. 2015;5(1): e006777. https:\/\/doi.org\/10.1136\/bmjopen-2014-006777.","journal-title":"BMJ Open"},{"issue":"4","key":"952_CR69","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s40263-017-0421-4","volume":"31","author":"Y Jiang","year":"2017","unstructured":"Jiang Y, McCombs JS, Park SH. A retrospective cohort study of acute kidney injury risk associated with antipsychotics. CNS Drugs. 2017;31(4):319\u201326. https:\/\/doi.org\/10.1007\/s40263-017-0421-4.","journal-title":"CNS Drugs"},{"issue":"8","key":"952_CR70","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-038247","volume":"10","author":"M Hojlund","year":"2020","unstructured":"Hojlund M, Lund LC, Herping JLE, Haastrup MB, Damkier P, Henriksen DP. Second-generation antipsychotics and the risk of chronic kidney disease: a population-based case-control study. BMJ Open. 2020;10(8): e038247. https:\/\/doi.org\/10.1136\/bmjopen-2020-038247.","journal-title":"BMJ Open"},{"issue":"5","key":"952_CR71","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-019868","volume":"8","author":"HY Wang","year":"2018","unstructured":"Wang HY, Huang CL, Feng IJ, Tsuang HC. Second-generation antipsychotic medications and risk of chronic kidney disease in schizophrenia: population-based nested case-control study. BMJ Open. 2018;8(5): e019868. https:\/\/doi.org\/10.1136\/bmjopen-2017-019868.","journal-title":"BMJ Open"},{"issue":"2","key":"952_CR72","doi-asserted-by":"publisher","first-page":"280","DOI":"10.2215\/CJN.02120216","volume":"12","author":"K Friedli","year":"2017","unstructured":"Friedli K, Guirguis A, Almond M, Day C, Chilcot J, Da Silva-Gane M, et al. Sertraline versus placebo in patients with major depressive disorder undergoing hemodialysis: a randomized, controlled feasibility trial. Clin J Am Soc Nephrol. 2017;12(2):280\u20136. https:\/\/doi.org\/10.2215\/CJN.02120216.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"19","key":"952_CR73","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1001\/jama.2017.17131","volume":"318","author":"SS Hedayati","year":"2017","unstructured":"Hedayati SS, Gregg LP, Carmody T, Jain N, Toups M, Rush AJ, et al. Effect of sertraline on depressive symptoms in patients with chronic kidney disease without dialysis dependence: the CAST randomized clinical trial. JAMA. 2017;318(19):1876\u201390. https:\/\/doi.org\/10.1001\/jama.2017.17131.","journal-title":"JAMA"},{"key":"952_CR74","doi-asserted-by":"publisher","first-page":"3293","DOI":"10.2147\/DDDT.S85418","volume":"9","author":"L Chen","year":"2015","unstructured":"Chen L, Greenberg WM, Brand-Schieber E, Wangsa J, Periclou A, Ghahramani P. Effect of renal impairment on the pharmacokinetics of levomilnacipran following a single oral dose of levomilnacipran extended-release capsule in humans. Drug Des Devel Ther. 2015;9:3293\u2013300. https:\/\/doi.org\/10.2147\/DDDT.S85418.","journal-title":"Drug Des Devel Ther."},{"issue":"10","key":"952_CR75","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.2215\/CJN.11271114","volume":"10","author":"C Renoux","year":"2015","unstructured":"Renoux C, Lix LM, Patenaude V, Bresee LC, Paterson JM, Lafrance JP, et al. Serotonin-norepinephrine reuptake inhibitors and the risk of AKI: a cohort study of eight administrative databases and meta-analysis. Clin J Am Soc Nephrol. 2015;10(10):1716\u201322. https:\/\/doi.org\/10.2215\/CJN.11271114.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"952_CR76","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/1471-2369-15-79","volume":"15","author":"V Dev","year":"2014","unstructured":"Dev V, Dixon SN, Fleet JL, Gandhi S, Gomes T, Harel Z, et al. Higher anti-depressant dose and major adverse outcomes in moderate chronic kidney disease: a retrospective population-based study. BMC Nephrol. 2014;15(1):79. https:\/\/doi.org\/10.1186\/1471-2369-15-79.","journal-title":"BMC Nephrol"},{"issue":"4","key":"952_CR77","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1111\/j.1440-1797.2012.01571.x","volume":"17","author":"CJ Tsai","year":"2012","unstructured":"Tsai CJ, el Loh W, Lin CH, Yu TM, Chan CH, Lan TH. Correlation of antidepressive agents and the mortality of end-stage renal disease. Nephrology (Carlton). 2012;17(4):390\u20137. https:\/\/doi.org\/10.1111\/j.1440-1797.2012.01571.x.","journal-title":"Nephrology (Carlton)"},{"key":"952_CR78","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.702789","volume":"12","author":"A Mariano","year":"2021","unstructured":"Mariano A, Di Lorenzo G, Jannini TB, Santini R, Bertinelli E, Siracusano A, et al. Medical comorbidities in 181 patients with bipolar disorder vs. schizophrenia and related psychotic disorders: findings from a single-center, retrospective study from an acute inpatients psychiatric unit. Front Psychiatry. 2021;12: 702789. https:\/\/doi.org\/10.3389\/fpsyt.2021.702789.","journal-title":"Front Psychiatry."},{"issue":"18","key":"952_CR79","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1056\/NEJMoa1915784","volume":"382","author":"NC Momen","year":"2020","unstructured":"Momen NC, Plana-Ripoll O, Agerbo E, Benros ME, Borglum AD, Christensen MK, et al. Association between mental disorders and subsequent medical conditions. N Engl J Med. 2020;382(18):1721\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1915784.","journal-title":"N Engl J Med"},{"issue":"1","key":"952_CR80","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13643-020-1274-3","volume":"9","author":"A Semahegn","year":"2020","unstructured":"Semahegn A, Torpey K, Manu A, Assefa N, Tesfaye G, Ankomah A. Psychotropic medication non-adherence and its associated factors among patients with major psychiatric disorders: a systematic review and meta-analysis. Syst Rev. 2020;9(1):17. https:\/\/doi.org\/10.1186\/s13643-020-1274-3.","journal-title":"Syst Rev"},{"issue":"4","key":"952_CR81","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1097\/HRP.0000000000000297","volume":"29","author":"CE Millett","year":"2021","unstructured":"Millett CE, Burdick KE. Defining heterogeneous cognitive trajectories in bipolar disorder: a perspective. Harv Rev Psychiatry. 2021;29(4):298\u2013302. https:\/\/doi.org\/10.1097\/HRP.0000000000000297.","journal-title":"Harv Rev Psychiatry"},{"issue":"1","key":"952_CR82","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.cell.2014.02.042","volume":"157","author":"JH Krystal","year":"2014","unstructured":"Krystal JH, State MW. Psychiatric disorders: diagnosis to therapy. Cell. 2014;157(1):201\u201314. https:\/\/doi.org\/10.1016\/j.cell.2014.02.042.","journal-title":"Cell"},{"issue":"2","key":"952_CR83","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/bdi.12609","volume":"20","author":"LN Yatham","year":"2018","unstructured":"Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Bond DJ, Frey BM, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018;20(2):97\u2013170. https:\/\/doi.org\/10.1111\/bdi.12609.","journal-title":"Bipolar Disord"},{"issue":"6","key":"952_CR84","first-page":"743","volume":"78","author":"CA Naughton","year":"2008","unstructured":"Naughton CA. Drug-induced nephrotoxicity. Am Fam Physician. 2008;78(6):743\u201350.","journal-title":"Am Fam Physician"},{"issue":"9","key":"952_CR85","first-page":"1250","volume":"9","author":"H Bendz","year":"1994","unstructured":"Bendz H, Aurell M, Balldin J, Mathe AA, Sjodin I. Kidney damage in long-term lithium patients: a cross-sectional study of patients with 15 years or more on lithium. Nephrol Dial Transplant. 1994;9(9):1250\u20134.","journal-title":"Nephrol Dial Transplant"},{"issue":"7","key":"952_CR86","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1002\/gps.1961","volume":"23","author":"EJ Van Melick","year":"2008","unstructured":"Van Melick EJ, Meinders AE, Hoffman TO, Egberts TC. Renal effects of long-term lithium therapy in the elderly: a cross-sectional study. Int J Geriatr Psychiatry. 2008;23(7):685\u201392. https:\/\/doi.org\/10.1002\/gps.1961.","journal-title":"Int J Geriatr Psychiatry"},{"key":"952_CR87","doi-asserted-by":"publisher","unstructured":"Chapter 2: definition, identification, and prediction of CKD progression. Kidney Int Suppl. (2011). 2013;3(1):63\u201372. https:\/\/doi.org\/10.1038\/kisup.2012.65.","DOI":"10.1038\/kisup.2012.65"},{"issue":"6","key":"952_CR88","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2165\/00002018-199921060-00002","volume":"21","author":"H Bendz","year":"1999","unstructured":"Bendz H, Aurell M. Drug-induced diabetes insipidus: incidence, prevention and management. Drug Saf. 1999;21(6):449\u201356. https:\/\/doi.org\/10.2165\/00002018-199921060-00002.","journal-title":"Drug Saf"},{"issue":"6","key":"952_CR89","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1681\/ASN.2015080907","volume":"27","author":"M Alsady","year":"2016","unstructured":"Alsady M, Baumgarten R, Deen PM, de Groot T. Lithium in the kidney: friend and foe? J Am Soc Nephrol. 2016;27(6):1587\u201395. https:\/\/doi.org\/10.1681\/ASN.2015080907.","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"952_CR90","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1007\/s11255-016-1352-6","volume":"48","author":"S Rej","year":"2016","unstructured":"Rej S, Pira S, Marshe V, Do A, Elie D, Looper KJ, et al. Molecular mechanisms in lithium-associated renal disease: a systematic review. Int Urol Nephrol. 2016;48(11):1843\u201353. https:\/\/doi.org\/10.1007\/s11255-016-1352-6.","journal-title":"Int Urol Nephrol"},{"key":"952_CR91","doi-asserted-by":"publisher","unstructured":"Finch CK, Brooks TWA, Yam P, Kelley KJT. Management and treatment of lithium-induced nephrogenic diabetes insipidus.\u00a0Therapy\u00a02005;2:669\u201375. https:\/\/doi.org\/10.1586\/14750708.2.4.669","DOI":"10.1586\/14750708.2.4.669"},{"issue":"3","key":"952_CR92","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.amjopharm.2007.09.003","volume":"5","author":"R Cohen","year":"2007","unstructured":"Cohen R, Wilkins KM, Ostroff R, Tampi RR. Olanzapine and acute urinary retention in two geriatric patients. Am J Geriatr Pharmacother. 2007;5(3):241\u20136. https:\/\/doi.org\/10.1016\/j.amjopharm.2007.09.003.","journal-title":"Am J Geriatr Pharmacother"},{"issue":"12","key":"952_CR93","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.2169\/internalmedicine.0170-17","volume":"57","author":"H Yamada","year":"2018","unstructured":"Yamada H, Katsumori Y, Kawano M, Mori S, Takeshige R, Mukai J, et al. Quetiapine-related acute kidney injury requiring transient continuous hemodiafiltration. Intern Med. 2018;57(12):1763\u20137. https:\/\/doi.org\/10.2169\/internalmedicine.0170-17.","journal-title":"Intern Med"},{"issue":"3","key":"952_CR94","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1097\/JCP.0000000000001042","volume":"39","author":"B DeLucia","year":"2019","unstructured":"DeLucia B. Clozapine-associated kidney injury complicated by lithium toxicity: a case report and literature review. J Clin Psychopharmacol. 2019;39(3):273\u20135. https:\/\/doi.org\/10.1097\/JCP.0000000000001042.","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"952_CR95","doi-asserted-by":"publisher","first-page":"249","DOI":"10.2478\/jccm-2020-0032","volume":"6","author":"M Tiglis","year":"2020","unstructured":"Tiglis M, Hurmuzache T, Bologa C, Neagu TP, Mirea L, Grintescu IM. Rhabdomyolysis-induced acute renal injury in a schizophrenic patient. J Crit Care Med (Targu Mures). 2020;6(4):249\u201352. https:\/\/doi.org\/10.2478\/jccm-2020-0032.","journal-title":"J Crit Care Med (Targu Mures)."},{"issue":"4","key":"952_CR96","doi-asserted-by":"publisher","first-page":"210","DOI":"10.5527\/wjn.v3.i4.210","volume":"3","author":"GV Prasad","year":"2014","unstructured":"Prasad GV. Metabolic syndrome and chronic kidney disease: Current status and future directions. World J Nephrol. 2014;3(4):210\u20139. https:\/\/doi.org\/10.5527\/wjn.v3.i4.210.","journal-title":"World J Nephrol."},{"issue":"10202","key":"952_CR97","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","volume":"394","author":"M Huhn","year":"2019","unstructured":"Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394(10202):939\u201351. https:\/\/doi.org\/10.1016\/S0140-6736(19)31135-3.","journal-title":"Lancet"},{"issue":"3","key":"952_CR98","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0230674","volume":"15","author":"A Dregan","year":"2020","unstructured":"Dregan A, McNeill A, Gaughran F, Jones PB, Bazley A, Cross S, et al. Potential gains in life expectancy from reducing amenable mortality among people diagnosed with serious mental illness in the United Kingdom. PLoS ONE. 2020;15(3): e0230674. https:\/\/doi.org\/10.1371\/journal.pone.0230674.","journal-title":"PLoS ONE"},{"issue":"2","key":"952_CR99","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/j.1468-2850.2009.01164.x","volume":"16","author":"AG Harvey","year":"2009","unstructured":"Harvey AG, Talbot LS, Gershon A. Sleep disturbance in bipolar disorder across the lifespan. Clin Psychol (New York). 2009;16(2):256\u201377. https:\/\/doi.org\/10.1111\/j.1468-2850.2009.01164.x.","journal-title":"Clin Psychol (New York)."},{"key":"952_CR100","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.660432","volume":"12","author":"H Grunze","year":"2021","unstructured":"Grunze H, Schaefer M, Scherk H, Born C, Preuss UW. Comorbid bipolar and alcohol use disorder: a therapeutic challenge. Front Psychiatry. 2021;12: 660432. https:\/\/doi.org\/10.3389\/fpsyt.2021.660432.","journal-title":"Front Psychiatry."},{"issue":"10","key":"952_CR101","doi-asserted-by":"publisher","first-page":"942","DOI":"10.4088\/jcp.v63n1013","volume":"63","author":"P Grof","year":"2002","unstructured":"Grof P, Duffy A, Cavazzoni P, Grof E, Garnham J, MacDougall M, et al. Is response to prophylactic lithium a familial trait? J Clin Psychiatry. 2002;63(10):942\u20137. https:\/\/doi.org\/10.4088\/jcp.v63n1013.","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"952_CR102","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1111\/j.1535-7597.2004.04515.x","volume":"4","author":"AM Kanner","year":"2004","unstructured":"Kanner AM. When thinking of lamotrigine and valproic acid, think \u201cpharmacokinetically\u201d! Epilepsy Curr. 2004;4(5):206\u20137. https:\/\/doi.org\/10.1111\/j.1535-7597.2004.04515.x.","journal-title":"Epilepsy Curr."},{"issue":"4","key":"952_CR103","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1111\/jgs.17623","volume":"70","author":"A Norgaard","year":"2022","unstructured":"Norgaard A, Jensen-Dahm C, Wimberley T, Svendsen JH, Ishtiak-Ahmed K, Laursen TM, et al. Effect of antipsychotics on mortality risk in patients with dementia with and without comorbidities. J Am Geriatr Soc. 2022;70(4):1169\u201379. https:\/\/doi.org\/10.1111\/jgs.17623.","journal-title":"J Am Geriatr Soc"},{"issue":"6","key":"952_CR104","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1111\/j.1399-5618.2009.00737.x","volume":"11","author":"F Ng","year":"2009","unstructured":"Ng F, Mammen OL, Wilting I, Sachs GS, Ferrier IN, Cassidy F, et al. The International Society for Bipolar Disorders (ISBD) consensus guidelines for the safety monitoring of bipolar disorder treatments. Bipolar Disord. 2009;11(6):559\u201395. https:\/\/doi.org\/10.1111\/j.1399-5618.2009.00737.x.","journal-title":"Bipolar Disord"},{"issue":"2","key":"952_CR105","doi-asserted-by":"publisher","first-page":"191","DOI":"10.31887\/DCNS.2011.13.2\/aleon","volume":"13","author":"AC Leon","year":"2011","unstructured":"Leon AC. Evaluation of psychiatric interventions in an observational study: issues in design and analysis. Dialogues Clin Neurosci. 2011;13(2):191\u20138. https:\/\/doi.org\/10.31887\/DCNS.2011.13.2\/aleon.","journal-title":"Dialogues Clin Neurosci"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-022-00952-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-022-00952-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-022-00952-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T09:21:20Z","timestamp":1665393680000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-022-00952-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,26]]},"references-count":105,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["952"],"URL":"https:\/\/doi.org\/10.1007\/s40263-022-00952-y","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,26]]},"assertion":[{"value":"29 August 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Charitable donations to the Jewish General Hospital Foundation, Fonds de recherche du Qu\u00e9bec\u2014Sant\u00e9 grant, and Canadian Institutes of Health Research grants #PJ8-169696 and #PJT-175191. No specific funding has been received for the conduct of this study and\/or the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"KB received a Canada Graduate Scholarship Social Sciences and Humanities Research Council Master\u2019s award, and McGill Faculty of Medicine Internal Studentship award. HS has a Canadian Institutes of Health Research fellowship award, Mitacs fellowship award, and an AGE-WELL award. SR receives a salary award from the Fonds de recherche du Qu\u00e9bec - Sant\u00e9, receives grant funding from Mitacs, is on a steering committee for AbbVie, and owns shares of Aifred Health. KTG has received payment for teaching from the Medical Doctor Psychotherapy Association of Canada and educational material preparation for psychedelic.support. JJD, PL, JD, CR, and ET report no conflicts of interest. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in this review apart from those disclosed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/competing interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"SR and KTG initiated the project. JJD, KB, PL, JD, SR, and KTG developed the search protocol. JJD, KB, and PL conducted the search. JJD and KB conducted the risk of bias assessments. JJD, KB, and KTG extracted the data, which was reviewed by PL and SR. All authors developed the outline and refined the summaries of results. JJD and KTG prepared tables and prepared the first draft of the article and led revisions. All authors reviewed and provided intellectual contributions to the draft manuscript and its revisions. All authors have read and approved the final submitted manuscript, and agree to be accountable for the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}